232 related articles for article (PubMed ID: 23980130)
1. In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.
Prajapati VK; Sharma S; Rai M; Ostyn B; Salotra P; Vanaerschot M; Dujardin JC; Sundar S
Am J Trop Med Hyg; 2013 Oct; 89(4):750-4. PubMed ID: 23980130
[TBL] [Abstract][Full Text] [Related]
2. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
3. Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India.
Srivastava S; Mishra J; Gupta AK; Singh A; Shankar P; Singh S
Parasit Vectors; 2017 Jan; 10(1):49. PubMed ID: 28137296
[TBL] [Abstract][Full Text] [Related]
4. Antimony susceptible
Ghosh S; Verma A; Kumar D; Deep DK; Ramesh V; Salotra P; Singh R
Microbiol Spectr; 2024 Jun; 12(6):e0402623. PubMed ID: 38712926
[TBL] [Abstract][Full Text] [Related]
5. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.
Deep DK; Singh R; Bhandari V; Verma A; Sharma V; Wajid S; Sundar S; Ramesh V; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005641. PubMed ID: 28575060
[TBL] [Abstract][Full Text] [Related]
6. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Rijal S; Ostyn B; Uranw S; Rai K; Bhattarai NR; Dorlo TP; Beijnen JH; Vanaerschot M; Decuypere S; Dhakal SS; Das ML; Karki P; Singh R; Boelaert M; Dujardin JC
Clin Infect Dis; 2013 Jun; 56(11):1530-8. PubMed ID: 23425958
[TBL] [Abstract][Full Text] [Related]
7. Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome.
Hendrickx S; Eberhardt E; Mondelaers A; Rijal S; Bhattarai NR; Dujardin JC; Delputte P; Cos P; Maes L
J Antimicrob Chemother; 2015 Nov; 70(11):3023-6. PubMed ID: 26253089
[TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.
Kumar D; Kulshrestha A; Singh R; Salotra P
Antimicrob Agents Chemother; 2009 Feb; 53(2):835-8. PubMed ID: 19015344
[TBL] [Abstract][Full Text] [Related]
9. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
10. Evaluating drug resistance in visceral leishmaniasis: the challenges.
Hendrickx S; Guerin PJ; Caljon G; Croft SL; Maes L
Parasitology; 2018 Apr; 145(4):453-463. PubMed ID: 27866478
[TBL] [Abstract][Full Text] [Related]
11. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.
Kulshrestha A; Bhandari V; Mukhopadhyay R; Ramesh V; Sundar S; Maes L; Dujardin JC; Roy S; Salotra P
Parasitol Res; 2013 Feb; 112(2):825-8. PubMed ID: 23239091
[TBL] [Abstract][Full Text] [Related]
12. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.
Carnielli JBT; Crouch K; Forrester S; Silva VC; Carvalho SFG; Damasceno JD; Brown E; Dickens NJ; Costa DL; Costa CHN; Dietze R; Jeffares DC; Mottram JC
EBioMedicine; 2018 Oct; 36():83-91. PubMed ID: 30268832
[TBL] [Abstract][Full Text] [Related]
13. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic adaptations of Leishmania donovani to recurrent miltefosine exposure and impact on sand fly infection.
Hendrickx S; Van Bockstal L; Bulté D; Mondelaers A; Aslan H; Rivas L; Maes L; Caljon G
Parasit Vectors; 2020 Feb; 13(1):96. PubMed ID: 32087758
[TBL] [Abstract][Full Text] [Related]
15. New insights with miltefosine unresponsiveness in Brazilian Leishmania infantum isolates.
Bhattacharya A; Ouellette M
EBioMedicine; 2018 Nov; 37():13-14. PubMed ID: 30314891
[No Abstract] [Full Text] [Related]
16. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.
Pérez-Victoria FJ; Sánchez-Cañete MP; Seifert K; Croft SL; Sundar S; Castanys S; Gamarro F
Drug Resist Updat; 2006; 9(1-2):26-39. PubMed ID: 16814199
[TBL] [Abstract][Full Text] [Related]
17. Natural Resistance of
Carnielli JBT; Monti-Rocha R; Costa DL; Molina Sesana A; Pansini LNN; Segatto M; Mottram JC; Costa CHN; Carvalho SFG; Dietze R
Am J Trop Med Hyg; 2019 Oct; 101(4):789-794. PubMed ID: 31436148
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model.
Hendrickx S; Mondelaers A; Eberhardt E; Delputte P; Cos P; Maes L
Antimicrob Agents Chemother; 2015 Aug; 59(8):4714-8. PubMed ID: 26014955
[TBL] [Abstract][Full Text] [Related]
19. Leishmania resistance to miltefosine associated with genetic marker.
Cojean S; Houzé S; Haouchine D; Huteau F; Lariven S; Hubert V; Michard F; Bories C; Pratlong F; Le Bras J; Loiseau PM; Matheron S
Emerg Infect Dis; 2012 Apr; 18(4):704-6. PubMed ID: 22469394
[No Abstract] [Full Text] [Related]
20. Immunosuppression of Syrian golden hamsters accelerates relapse but not the emergence of resistance in Leishmania infantum following recurrent miltefosine pressure.
Hendrickx S; Bulté D; Van den Kerkhof M; Cos P; Delputte P; Maes L; Caljon G
Int J Parasitol Drugs Drug Resist; 2019 Apr; 9():1-7. PubMed ID: 30562667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]